5-LOXIN Reduces OA Symptoms

MORRISTOWN, N.J.—PL Thomas (PLT), in alliance with Laila Nutraceuticals, India, jointly announced the publication of a new study in Arthritis Research & Therapy using their exclusive dietary supplement ingredient, 5-LOXIN®. In the study, 5-LOXIN supplementation conferred clinically and statistically significant improvements in pain scores and physical function scores in osteoarthritis (OA) patients at doses of 100 and 250 mg/d. Significant improvements in pain score and functional ability were recorded seven days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, a significant reduction in synovial fluid MMP activity, enzymes, which damage connective tissue, was noted. 5-LOXIN was found to be well tolerated with no safety concerns.
Siba Raychaudhuri, a faculty member of the University of California, Davis, led the study. Seventy-five OA patients were included in the study. Dived into three groups of 25, the patients were given either 100 mg/d of 5-LOXIN, 250 mg/d of 5-LOXIN or a placebo for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools (VAS - visual analog scale, Lequesne's Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at baseline and at days 7, 30, 60 and 90. Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid of the knee from OA patients.
According to the authors, “In this study, the compound was shown to have no major adverse effects in our osteoarthritis patients. It is safe for human consumption and even for long-term use.”

www.PLThomas.com